SCHEMBL25814838

SCHEMBL25814838

Cc1c(Br)cc(C(=O)c2c(CCO)oc3cc(O)c(O)cc23)cc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC22A12 Q96S37 9/20 0.56
▸ TTR P02766 4/20 0.46
▸ EYA3 Q99504 6/20 0.46
▸ CYP2C19 P33261 4/20 0.44
▸ CYP2C9 P11712 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ EYA2 O00167 1/20 0.44
▸ ABCC4 O15439 1/20 0.44
▸ PLIN1 O60240 1/20 0.44
▸ NR1I2 O75469 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ ABCB11 O95342 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ ALB P02768 1/20 0.44
▸ ESR1 P03372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25814844 0.91 SLC22A12 (0.49) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL25814819 0.87 SLC22A12 (0.73) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL25814835 0.85 SLC22A12 (0.65) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL25814830 0.82 TTR (0.64) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL25814823 0.80 SLC22A12 (0.62) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL25814856 0.78 SLC22A12 (0.48) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL22072730 0.78 SLC22A12 (0.88) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL25814817 0.72 SLC22A12 (0.84) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL25814859 0.70 EYA3 (0.44) SLC22A12TTREYA3CYP2C19CYP2C9
SCHEMBL18058593 0.69 CYP2C19 (0.81) SLC22A12TTREYA3CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ARTHROSI THERAPEUTICS, INC. 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ATP6V1B1, REN, CYP27B1 SLC22A12 620/4885TTR 201/4885EYA3 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback